Bruker (NASDAQ:BRKR) Issues FY 2024 Earnings Guidance

Bruker (NASDAQ:BRKR) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.360-2.410 for the period, compared to the consensus EPS estimate of 3.590. The company issued revenue guidance of $3.3 billion-$3.4 billion, compared to the consensus revenue estimate of $3.4 billion. Bruker also updated its FY24 guidance to $2.36-2.41 EPS.

Bruker Stock Performance

Shares of BRKR stock traded down $1.67 on Wednesday, hitting $59.67. The company’s stock had a trading volume of 1,162,502 shares, compared to its average volume of 1,067,669. Bruker has a fifty-two week low of $54.55 and a fifty-two week high of $94.86. The company has a market capitalization of $9.03 billion, a PE ratio of 24.98, a PEG ratio of 2.32 and a beta of 1.20. The stock’s 50 day moving average is $64.08 and its 200-day moving average is $66.56. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.75 and a current ratio of 1.65.

Bruker (NASDAQ:BRKR) last announced its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). The business had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. The firm’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.74 earnings per share. Equities research analysts expect that Bruker will post 2.61 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Monday, September 2nd were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.34%. The ex-dividend date was Friday, August 30th. Bruker’s dividend payout ratio is currently 8.30%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on BRKR shares. Wolfe Research lowered shares of Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. Barclays cut their price target on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a report on Wednesday. TD Cowen decreased their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a report on Wednesday. Wells Fargo & Company cut their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, The Goldman Sachs Group decreased their price target on Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research note on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Bruker has a consensus rating of “Moderate Buy” and an average price target of $79.36.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.